FDA Approves AstraZeneca's SEROQUEL(R) For Bipolar Depression
PR Newswire - WILMINGTON, Del., Oct. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL(R) (quetiapine fumarate) for the treatment of patients with depressive episodes
Source: sev.prnewswire.com
Danish shares higher at mid-day led by Bang & Olufsen; Moller-Maersk
Forbes - Lundbeck was up 2 dkr at 164.75, having yesterday been hit by profit-taking following better-than-expected third-quarter sales of its Lexapro depression treatment in the US, announced earlier in the week. Nordea Bank was up 0.75 dkr at 89.75, Sydbank
Source: www.forbes.com
Foolish Forecast: Greener Forest Labs
MSN MoneyCentral - Yet after a rocky start, revenues and earnings have grown to record levels because of Forest Labs' stable of other products, including Lexapro, which succeeded Celexa for depression treatment. Last October, Chairman and CEO Howard Solomon said, "We
Source: news.moneycentral.msn.com
Click here for more information about elderly depression elderly depression
<< Home